driving green

Electric buses are on track to roll into Houston

METRO is moving toward the purchase of only zero-emission buses by 2030. Image courtesy of NovaBus

Within the next year or so, you’ll see electric-powered buses buzzing around Bayou City.

The Metropolitan Transit Authority of Harris County (METRO) recently awarded a $22 million contract to Saint-Eustache, Canada-based Nova Bus for the production of 20 battery-powered electric buses. The contract includes an option for another 20 buses.

The first 20 buses, to be manufactured at the Nova Bus factory in Plattsburgh, New York, are expected to be on local roads sometime in in late 2022 or early 2023. They’ll run on the 402 Bellaire Express (Quickline) and 28 OST-Wayside routes.

METRO also plans to test three to five electric buses powered by hydrogen fuel cells. Furthermore, METRO is a member of the Automated Bus Consortium, a national organization of transportation agencies working toward development of a full-size, electric-powered automated bus.

METRO is moving toward the purchase of only zero-emission buses by 2030. It eventually wants to operate more than 1,200 electric buses throughout its system. All types of buses account for 1 percent of transportation-caused greenhouse gases in Houston, according to METRO.

Nova Bus, owned by Swedish automaker Volvo, says its electric vehicles reduce greenhouse gas emissions while also cutting maintenance costs.

“METRO is paying close attention to the climate assessments showing Houston will grapple with rising temperatures and more frequent weather events. It is more critical than ever that METRO map out a plan to not only prepare for these events but to mitigate the impact they have on our community as much as we can,” Carrin Patman, chairwoman of the METRO board, says in a recent presentation.

President Biden has tapped Patman, a Houston attorney, to be the U.S. ambassador to Iceland.

Patman has appointed METRO board members Chris Hollins, former Harris County clerk, and Terry Morales, an executive at Amegy Bank, to shepherd the agency’s efforts to combat climate change.

“The impact of climate change is a significant threat to the health and safety of our community,” Hollins says in the METRO presentation. “METRO can and will be a leader in helping the region respond to this challenge.”

“Beginning with the deployment of clean fleet technology,” he adds, “METRO will lead the way in green transit. METRO is taking a holistic approach — transforming not just our buses, but all our business practices — to increase sustainability, resiliency, and carbon emissions reduction.”

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted